FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2950401596> ?p ?o ?g. }

• W2950401596 abstract "Background: Intravenous immunoglobulin (IVIG) is the mainstay of treatment for Kawasaki Disease (KD). Due to the consolidation of IVIG manufacturers in 2008, different preparations of IVIG are currently available in Canada. An increase in adverse effects, especially hemolytic anemia, has been observed. Objective: To characterize the natural history of IVIG-associated hemolytic anemia in KD. Methods: A single-centre retrospective study was conducted at Toronto’s SickKids Hospital between January 2002 and December 2012. Medical records of all KD patients were reviewed and hemolytic anemia identified (drop in hemoglobin ≥20mg/dl post-IVIG treatment with 2 or more of the following criteria: reticulocytosis, positive direct anti-globulin test (DAT), and morphological changes on blood film). For statistical analysis, Chi-square tests and ANOVA with Tukey’s post-hoc correction for multiple comparisons were utilized. Results: Between 2002 and 2008, 2 of 370 patients diagnosed with KD who received Iveegam had hemolytic anemia (0.5%). After 2008, the rates of IVIG-associated hemolysis were as follows: Privigen 17% (8/48, p<0.001), Gammagard 3.3% (4/121) and Gamunex 2.3% (3/130). Retreatment rates were significantly higher in the hemolysis group (64% vs. 22%, p<0.001), and there was a trend showing more patients with larger aneurysms (Z-score >5) in the hemolysis group (17% vs. 5.3%). All patients who hemolyzed had non-O+ blood types. Out of the 17 patients with hemolysis, 9 required red cell transfusions (60%). Starting in 2012, a detailed hemolysis work-up was included as standard protocol for all KD patients. Hemolysis was mediated by anti-blood group A & B antibodies resulting in DAT positivity, but no complement fixation. This extravascular hemolysis was maximal at 72 hours post-IVIG infusion and appeared to be dose dependent. Conclusions: Hemolysis is seen in up to 17% of those receiving new IVIG preparations, which also appear to be less efficacious - associated with treatment failure and, possibly, poor coronary outcome. There are important implications for patient safety. Further study is required to develop evidence-based guidelines to improve our management of these children." @default.
• W2950401596 created "2019-06-27" @default.
• W2950401596 creator A5001317731 @default.
• W2950401596 creator A5005118193 @default.
• W2950401596 creator A5021915807 @default.
• W2950401596 creator A5027489789 @default.
• W2950401596 creator A5038297989 @default.
• W2950401596 creator A5040872283 @default.
• W2950401596 creator A5062101214 @default.
• W2950401596 creator A5084628375 @default.
• W2950401596 date "2015-04-28" @default.
• W2950401596 modified "2023-09-27" @default.
• W2950401596 title "Abstract O.48: Intravenous Immunoglublin-Associated Hemolysis in Kawasaki Disease" @default.
• W2950401596 doi "https://doi.org/10.1161/circ.131.suppl_2.o48" @default.
• W2950401596 hasPublicationYear "2015" @default.
• W2950401596 type Work @default.
• W2950401596 sameAs 2950401596 @default.
• W2950401596 citedByCount "0" @default.
• W2950401596 crossrefType "journal-article" @default.
• W2950401596 hasAuthorship W2950401596A5001317731 @default.
• W2950401596 hasAuthorship W2950401596A5005118193 @default.
• W2950401596 hasAuthorship W2950401596A5021915807 @default.
• W2950401596 hasAuthorship W2950401596A5027489789 @default.
• W2950401596 hasAuthorship W2950401596A5038297989 @default.
• W2950401596 hasAuthorship W2950401596A5040872283 @default.
• W2950401596 hasAuthorship W2950401596A5062101214 @default.
• W2950401596 hasAuthorship W2950401596A5084628375 @default.
• W2950401596 hasConcept C126322002 @default.
• W2950401596 hasConcept C159654299 @default.
• W2950401596 hasConcept C203014093 @default.
• W2950401596 hasConcept C2776175824 @default.
• W2950401596 hasConcept C2777799521 @default.
• W2950401596 hasConcept C2778248108 @default.
• W2950401596 hasConcept C2778917026 @default.
• W2950401596 hasConcept C2778986270 @default.
• W2950401596 hasConcept C2779902561 @default.
• W2950401596 hasConcept C71924100 @default.
• W2950401596 hasConcept C90924648 @default.
• W2950401596 hasConceptScore W2950401596C126322002 @default.
• W2950401596 hasConceptScore W2950401596C159654299 @default.
• W2950401596 hasConceptScore W2950401596C203014093 @default.
• W2950401596 hasConceptScore W2950401596C2776175824 @default.
• W2950401596 hasConceptScore W2950401596C2777799521 @default.
• W2950401596 hasConceptScore W2950401596C2778248108 @default.
• W2950401596 hasConceptScore W2950401596C2778917026 @default.
• W2950401596 hasConceptScore W2950401596C2778986270 @default.
• W2950401596 hasConceptScore W2950401596C2779902561 @default.
• W2950401596 hasConceptScore W2950401596C71924100 @default.
• W2950401596 hasConceptScore W2950401596C90924648 @default.
• W2950401596 hasIssue "suppl_2" @default.
• W2950401596 hasLocation W29504015961 @default.
• W2950401596 hasOpenAccess W2950401596 @default.
• W2950401596 hasPrimaryLocation W29504015961 @default.
• W2950401596 hasRelatedWork W1580538130 @default.
• W2950401596 hasRelatedWork W1958370520 @default.
• W2950401596 hasRelatedWork W2001088022 @default.
• W2950401596 hasRelatedWork W2086587484 @default.
• W2950401596 hasRelatedWork W2263438737 @default.
• W2950401596 hasRelatedWork W2330105585 @default.
• W2950401596 hasRelatedWork W2397206134 @default.
• W2950401596 hasRelatedWork W2566458076 @default.
• W2950401596 hasRelatedWork W2909474449 @default.
• W2950401596 hasRelatedWork W2968076071 @default.
• W2950401596 hasVolume "131" @default.
• W2950401596 isParatext "false" @default.
• W2950401596 isRetracted "false" @default.
• W2950401596 magId "2950401596" @default.
• W2950401596 workType "article" @default.